SIGY Sigyn Therapeutics, Inc.

CIK 0001642159 11 ready 8-Ks latest August 15, 2025, 7:59 PM ET RSS · JSON

Activity: NORMAL 0 filings / 30d vs 0 baseline

Ready 8-Ks 11

Latest filing February 20, 2026, 6:59 PM ET

Top materiality 0.80

Event mix other_material ×6 · leadership ×3 · debt ×2

Sentiment 1 pos · 1 neg · 9 neu

Executive change recent →

Recent 8-K filings for SIGY

Highest-materiality recent filing

Three directors resign after D&O insurance lapse; $550K convertible note issued

August 15, 2025, 7:59 PM ET leadership materiality 0.80 negative item 1.01 item 3.02 item 5.02 item 8.01 item 9.01

Directors Richa Nand, Michael Ryan, and Christopher Wetzel resigned on Aug 7-8, 2025 due to lapse of D&O coverage.
D&O insurance policy expired Aug 4, 2025; no replacement in place; company evaluating alternatives.

August 15, 2025, 7:59 PM ET leadership materiality 0.80 negative item 1.01 item 3.02 item 5.02 item 8.01 item 9.01

Three directors resign after D&O insurance lapse; $550K convertible note issued

Directors Richa Nand, Michael Ryan, and Christopher Wetzel resigned on Aug 7-8, 2025 due to lapse of D&O coverage.
March 7, 2025, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Sigyn Therapeutics CFO Gerald DeCiccio Retires; CEO James Joyce Appointed Interim CFO

CFO Gerald DeCiccio retired effective February 26, 2025, with no disagreement with the company.
April 16, 2024, 7:59 PM ET debt materiality 0.70 neutral item 1.01 ◈ Material Agreements

Sigyn Therapeutics converts $841k debentures to Series B Preferred; extends other debt to 2025

Brio Capital converts $220,420 debentures into 292.4 shares of Series B Convertible Preferred Stock.

Appointed (interim)

interim Chief Financial Officer

SIGY · Sigyn Therapeutics, Inc.

Mr. James Joyce, our Chief Executive Officer, will serve as our interim Chief Financial Officer.

Departed

Chief Financial Officer

SIGY · Sigyn Therapeutics, Inc.

On February 26, 2025, our Chief Financial Officer, Mr. Gerald DeCiccio provided us a notice of retirement, effective immediately.

Appointed

Director

SIGY · Sigyn Therapeutics, Inc.

On January 11, 2025, our Board of Directors appointed Michael Ryan to our Board of Directors.

Max materiality 0.80 · Median 0.50 · Most common event other_material

1 positive 1 negative 9 neutral